Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kombinerer Stellate Ganglion Block med langvarig eksponering for PTSD

Kombination af stellate ganglionblok med langvarig eksponering for PTSD: et randomiseret klinisk forsøg

The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment.

The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.

Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

140

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Texas
      • Fort Hood, Texas, Forenede Stater, 76544
        • Rekruttering
        • Carl R. Darnall Army Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Caleb Dickinson, DO
      • Fort Sam Houston, Texas, Forenede Stater, 78234
        • Rekruttering
        • Brook Army Medical Center (BAMC)
        • Kontakt:
        • Ledende efterforsker:
          • Wilson B Pfeiffer, Do
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • University of Texas Health Science Center at San Antonio
        • Kontakt:
        • Ledende efterforsker:
          • Alan Peterson, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Active duty and retired military service members ages 18-65 years
  2. PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale
  3. Able to speak and read English (due to standardization of outcome measures)
  4. Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at a military treatment facility (MTF) where the stellate ganglion block will be placed.

Exclusion Criteria:

  1. Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index - Suicidality Subscale and the Self-Injurious Thoughts and Behaviors Interview short form) and corroborated by a clinical risk assessment by a credentialed provider.
  2. Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization (as determined by clinical judgment)
  3. Symptoms of moderate to severe substance use (to include alcohol) warranting immediate intervention based on clinical judgment.
  4. Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
  5. Pregnancy or breastfeeding
  6. Current anticoagulant use
  7. History of bleeding disorder
  8. Infection or mass at injection site
  9. Myocardial infarction within 6 months of procedure
  10. Pathologic bradycardia or irregularities of heart rate or rhythm
  11. Symptomatic hypotension
  12. Phrenic or laryngeal nerve palsy
  13. History of glaucoma
  14. Uncontrolled seizure disorder
  15. History of allergy to local anesthetics
  16. Current use of Class III antiarrhythmics

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Stellate Ganglion Block

One time administration of a stellate ganglion block

6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion

Andre navne:
  • Naropin
Placebo komparator: Sham SGB

One time administration

6.5cc of Normal Saline one time into the stellate ganglion.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis.

Baseline and at 1-month, 3-month, and 6-month follow-up assessments
Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

A 20-item self-report measure that assesses the presence and change in severity of PTSD symptoms using the Diagnostic and Statistical Manual of mental disorders (DSM-5). Total severity scores range from 0 to 80 with higher score indictive of greater PTSD severity.

Baseline and at 1-month, 3-month, and 6-month follow-up assessments

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Patient Health Questionnaire-9 items (PHQ-9)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

A 9-item self-report measure that assesses the presence and change in severity of depressive symptoms. Total scores range from 0 to 27 with higher scores reflective of greater severity.

Baseline and at 1-month, 3-month, and 6-month follow-up assessments
General Anxiety Disorder Screener - 7 Items (GAD-7)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

A 9-item self-report measure that assesses the presence and change in severity of general anxiety symptoms. Total scores range from 0 to 21 with higher scores reflective of greater severity.

Baseline and at 1-month, 3-month, and 6-month follow-up assessments
Posttraumatic Cognitions Inventory (PTCI)
Tidsramme: Baseline and at 1-month, 3-month, and 6-month follow-up assessments

A 36-item self-report measure that assesses change in self-blame, negative cognitions about self, and negative cognitions about the world following trauma exposure. Total scores range from 33 to 231 with higher scores reflective of more problematic cognitions.

Baseline and at 1-month, 3-month, and 6-month follow-up assessments
Psychophysiological arousal - Galvanic Skin Response
Tidsramme: Two weeks

Change in Psychophysiological data collected from a smart watch measuring galvanic skin response

Two weeks
Psychophysiological arousal - Skin Temperature
Tidsramme: Two weeks

Change in Psychophysiological data collected from a smart watch measuring skin temperature

Two weeks
Psychophysiological arousal - Heart Rate
Tidsramme: Two weeks

Change in Psychophysiological data collected from a smart watch measuring heart rate

Two weeks
Psychophysiological arousal - Interbeat Interval
Tidsramme: Two weeks

Change in Psychophysiological data collected from a smart watch measuring interbeat interval

Two weeks
Psychophysiological arousal - Three-Dimensional Accelerometer Movement
Tidsramme: Two weeks

Change in Psychophysiological data collected from a smart watch measuring three-dimensional accelerometer movement

Two weeks
Psychophysiological arousal - Electrodermal Activity
Tidsramme: Two weeks

Change in Psychophysiological data collected from a smart watch measuring electrodermal activity

Two weeks
Psychophysiological arousal - Photoplethysmography
Tidsramme: Two weeks

Change in Psychophysiological data collected from a smart watch measuring photoplethysmography

Two weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Alan Peterson, PhD, The University of Texas Health Science Center at San Antonio

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. februar 2024

Primær færdiggørelse (Anslået)

31. marts 2028

Studieafslutning (Anslået)

31. august 2028

Datoer for studieregistrering

Først indsendt

17. april 2023

Først indsendt, der opfyldte QC-kriterier

1. juni 2023

Først opslået (Faktiske)

5. juni 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner